Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure

NCT00799435 on ClinicalTrials.gov · last registry update 2020-09-04

Stopped early, having planned 2 participants. The sponsor logged completion for April 2012. Primary outcome, as filed: Change in Aortic Stiffness, as Measured by the Change in the Mean Aortic Pulse Wave Velocity. exenatide is approved in the US, but not for heart failure — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: TERMINATED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Baylor College of Medicine
Sponsor type: Other
Enrollment: 2
Started: 2009-07
Primary completion: 2012-04 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Aortic Stiffness, as Measured by the Change in the Mean Aortic Pulse Wave Velocity

Conditions studied

Diabetes Mellitus, Type 2 · Heart Failure, Diastolic

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.